Viatris Inc. (VTRS)
Nasdaq · Healthcare · Drug Manufacturers - Specialty & Generic
$17.62+0.11%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $20.2B
- Forward P/E
- 6.6
- Dividend yield
- 2.7%
- 52-week range
- $9.69 – $18.43
- 52-week change
- +73.57%
- EPS (trailing)
- −$0.36
- Analyst rating
- 2.0 Buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $14.3B (−2.98%)
- Operating margin
- −18.6%
- Diluted EPS
- −$3.00
- Free cash flow
- $1.9B
From the company’s annual report on SEC EDGAR.
About Viatris Inc.
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions.
Headquarters: Canonsburg, United States · 30,000 employees · viatris.com